COMPARISON OF PROSTATE SPECIFIC ANTIGEN DENSITY IN PATIENTS WHO HAD UNDERGONE RADICAL RETROPUBIC PROSTATECTOMY WITH PSA LEVELS BETWEEN 4.0 TO 1 0.0 NG./ML. AND HISTOPATHOLOGICAL EXAMINATION

Yıl 1999, Cilt: 12 Sayı: 4, 186 - 190, 03.12.2016

Türker Koksal Murat Tunç İrfan Orhan Mustafa Usta İşın Kılıçaslan Tarık Esen

Öz

Objective: We analyzed PSA density in patients who had undergone radical retropubic prostatectomy (RRP) with PSA levels between 4.0 to 10.0 ng/ml and compared these values to histopathological examination.
Methods: Between July 1992 and December 1997, we performed 117 radical retropubic prostatectomies for clinically localized prostatic carcinoma. Thirty patients whose serum PSA levels were between 4.0 to
10.0 ng/ml, were selected as the study group among all. No patients received neoadjuvant therapy, including androgen deprivation or radiation therapy. The age, preoperative PSA level (Hybritech Tandem assay), PSA density, transrectal ultrasound and Gleason pattern score of transrectal ultrasound guided biopsy and prostatectomy specimens were examined.
Results: The age of the patients ranged from 56 to 76 years and the mean age was 63.83 ± 5.01 years. Preoperative PSA levels ranged between 4.0 to 10.0 ng/ml. The mean value was 7.0 ± 1.60 ng/ml. The follow up period of the patients was between 21 and 78 months. The mean follow up was 49.8 ± 14.79 (median: 51) months. Prostate volume ranged from 18 to 110 cc and mean prostate volume was 44.81 ±
23.02 cc (median: 42.50 cc). PSA density ranged from
0.08 to 0.55 ng/ml/cc, mean PSA density was 0.19 ±
0.11 ng/ml/cc (median: 0.15 ng/ml/cc). Using 0.15 PSA density as the cut point, 12 (40%) patients had PSA density <0.15 ng/ml/cc. Of these, radical prostatectomy specimen pathological stage was pT2 in 4 (33%) cases, pT3a in 5 (42%), pT3c in 3 (25%). No patient had lymphatic invasion. PSA density was >
0.15 ng/ml/cc in 18 (60%) patients. Of these, radical prostatectomy specimen pathological stage was pT2 in 7 (39%) cases, pT3a in 8 (44%), pT3c in 3 (17%) and 1 patient (6%) had lymph node positive. The follow
up of PSA levels revealed recurrence in 6 (20%) patients. The period of these recurrences: mean time to recurrence was 17.3 ± 19.54 (median: 24.5 months) months with a range of 3 and 53 months. Five of 6 patients (83%) had PSA density >0.15 ng/ml/cc.
Conclusion: There is still some controversy regarding the treatment algorithm in cases with prostate cancer and PSA levels between 4.0 to 10.0 ng/ml. Recent studies, have underlined that free to total serum PSA ratio has a higher specificity than PSA density for cases with a PSA levels between 4.0 to 10.0 ng/ml in detecting and screening prostate cancer. But, PSA density has shown to be > 0.15 ng/ml/cc in 60% cases who had undergone radical retropubic prostatectomy for localized prostate cancer and PSA levels between
4.0 to 10.0 ng/ml. Furthermore, 39% of them had organ confined disease while 6% had lymphatic invasion.
Key Words: Prostate carcinoma, Prostate specific antigen, Prostate specific antigen density, Pathological stage

Kaynakça

• Oesterling JE. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991.145:907-923.
• Catalona JC, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. Hew Engl J Med 1991:324:1 156-1 161.
• Catalona WJ, Richie JP, Ahmann PR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994:151:1283-1290.
• Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin north Am 1997,24:283- 291.
• Partin AW, Carter fIB, Chan DW, et ai. Prostate specific antigen in the staging of localized prostate cancer. Influence of tumor differentiation, tumor volume and benign hiperplasia. J Urol 1990:143:747-752.
• Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989; 142:1011-1017.
• Lange PH, Ercole CJ, Lightner DJ, et al. The value of prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989; 141:873- 879.
• Benson MC, Whang IS, Olsson CA. The use of prostate specific antigen density to enhance the predictive value of intermadiate levels of serum PSA. J Urol 1992; 147:81 7-821.
• Oesterling JE, Jacobsen SJ, Chute CO, et al. Serum prostate specific antigen in a community-based population of healthy man: establishment of age specific reference ranges. JAMA 1993:270:860- 864.
• Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994; 152:1163- 1 167.
• 1. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA 1995:274:1214-1220.
• Zlotta AR, Djavan B, Marberger M, et al. Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol 1997; 157:1315-1321.
• Gleason DP. Classification of prostatic carcinoma. Cancer Chemother Rep ¡966:50:125-128.
• Esteve J, Kricker A, Ferlay J, et al. Facts and figures of cancer in the European cummunity. Lyon, France: International agency for research on cancer 1993:1-26.
• Epstein Jl, Walsh P, Brendler CB. Radical prostatectomy for Impalpable prostate cancer: The Johns Hopkins experience with tumors found on transurethral resection (stages Tla and Tib) and on needle biopsy (stageTIc). J Urol 1994; 152:1 721- 1729.
• Puppo P, Perachino M. Clinical stage, prostate specific antigen and Gleason grade to predict extracapsular disease or nodal metastasis in men with newly diagnosed, previously untreated prostate cancer. Eur Urol 1997;32:273-279.
• 7. Kleer E, Oesterling JE. PSA and staging of localized prostate cancer. Urol Clin north Am 1993:20:695- 704.
• Partin AW, Carter H B, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differention, tumor volume and benign hyperplasia. J Urol 1990; 143:747-316.
• Stamey TA, Yang H, flay AR, et ai Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. Hew Eng! J Med 1987,31 7:909-916.
• Babaian RJ, Camps JL. The role of prostate specific antigen as a part of the diagnostic triad and as a guide when to perform a biopsy. Cancer 1991;68:2060-2063.
• Stormont TJ, Farrow GM, Myers RP, et al. Clinical stage Bo or Tic prostate cancer: nonpalpable disease identified by elevated serum prostate specific antigen concentration. Urology 1993; 41:3-8.
• Lemer SE, Seay TM, Blute ML, et al. Prostate specific antigen detected prostate cancer (clinical stage Tic): An interim analysis. J Urol 1996; 155:821 -826.
• Partin AW, Yoo J, Carter B, et al. The use of prostate specific antigen clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993,150:110-114.
• Partin AW, Lee BR, Carmichael M, et al. Radical prostatectomy for high grade disease. A réévaluation 1994. J Urol 1994,151:1583-1586.
• Catalona JC, Smith DS, Ratliff TL, et al. Detection of organ - confined prostate cancer is increased through prostate specific antigen based screening. JAMA 1993;270:948-954.
• Akda$ A, Tarcan A, Türkeri L, et at. The impact of prostate-specific antigen its density and the Gleason score in the prediction of extracapsular disease in prostate carcinoma. Eur Urol 199 7;31:311-316.
• Bretton PR, Evans WP, Borden JD, et al. The use of prostate specific antigen density to improve the sensivity of prostate specific antigen in detecting prostate carcinoma. Cancer 1994;74:2991-2993.
• Catalona WJ, Richie JP, deKernion JB, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen
• density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994;152:2031-2036.
• Cookson MS, Floyd MR, Ball TP, et at The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal recta! examination and intermadiate prostate specific antigen levels. J Urol 1995;154:1070-1073.
• Bazinet M, Meshref AW, Trudel C, et al. Prospective evaluation of prostate specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 1994;43:44-51.
• Ziotta AR, Djavan B, Petein M, et at. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen density less than 10 ng./ml. J Urol 1998; 160:2089- 2095.
• Christenssen A, Bjôrk T, Tiilsson, et al. Serum prostate specific antigen complexed to al- antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150:100-105.
• Ring C, Friese J, Lauren L, et al. Measurement on IMx of free and total forms of prostate specific antigen for differention of patients with benign prostatic hyperplasia and prostate cancer. Clin Chem 1994;40:1007-1010.
• Bangma Cfi, Rranse R, Blijenberg BG, et al. The value of screening test in the detection of prostate cancer. Paît I. Results of a retrospective evaluation of 1726 men. Urology 1995;46:773-778.
• Prestigiacoma AF, Lilja 11, Petterson R, et al. A
• comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol
• ;156:350-194.
• Bangma Cli, Rietbergen JBW, Rranse R, et al. The free-to-totai prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol 1997,157:2191-2196.